Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
Dublin, Ireland: An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumour activity in a number of cancers including those ...
Nov 14, 2018
0
3